Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
暂无分享,去创建一个
Masatoshi Kudo | Osamu Yokosuka | Gianluca Masi | M. Kudo | J. Bruix | J. Llovet | R. Finn | O. Yokosuka | G. Bodoky | G. Meinhardt | A. Cheng | P. Ross | Yi‐Hsiang Huang | A. Granito | G. Masi | S. Qin | O. Rosmorduc | T. Song | R. Gérolami | P. Merle | Richard S Finn | Jordi Bruix | Josep M Llovet | M. Leberre | György Bodoky | Ann-Lii Cheng | M. Pracht | V. Breder | J. Bronowicki | I. Ollivier-Hourmand | A. Baumhauer | G. Han | Olivier Rosmorduc | Shukui Qin | Gerold Meinhardt | Yi-Hsiang Huang | Tianqiang Song | Jean-Pierre Bronowicki | Philippe Merle | Alessandro Granito | Marc Pracht | Valeriy Breder | René Gerolami | Paul J Ross | Isabelle Ollivier-Hourmand | Marie-Aude LeBerre | Annette Baumhauer | Guohong Han
[1] P. Schirmacher,et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.
[2] M. Vinciguerra,et al. Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib. , 2016, Current drug targets.
[3] A. Zhu,et al. Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial , 2016, Clinical Cancer Research.
[4] F. Izzo,et al. Phase III randomized study of second line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). , 2016 .
[5] J. Bruix,et al. Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. , 2016, Gastroenterology.
[6] L. Schwartz,et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). , 2016 .
[7] Joon-Oh Park,et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. , 2015, The Lancet. Oncology.
[8] J. Bruix,et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Ying Cheng,et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Y. Imai,et al. JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan , 2014, Liver Cancer.
[11] J. Bruix,et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. , 2014, Journal of hepatology.
[12] M. Kudo,et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.
[13] J. Bruix,et al. Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second‐line trial design , 2013, Hepatology.
[14] Antonio Gasbarrini,et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. , 2013, European journal of cancer.
[15] M. Kudo,et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] L. Jeng,et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Kudo,et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Brix,et al. Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model , 2013, Molecular Cancer Therapeutics.
[19] D. Sargent,et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[20] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[21] J. Blay,et al. Effi cacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib ( GRID ) : an international , multicentre , randomised , placebo-controlled , phase 3 trial , 2013 .
[22] J. Bruix,et al. Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.
[23] V. Mazzaferro,et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .
[24] D. Zopf,et al. Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.
[25] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[26] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[27] M. Neary,et al. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.
[28] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[29] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[30] M. Neary,et al. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer , 2010, Health and Quality of Life Outcomes.
[31] D. Cella,et al. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[32] D. Auclair,et al. BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.
[33] L Pagliaro,et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.